Metformin: New Preparations and Nonglycemic Benefits
@article{Fujita2017MetforminNP, title={Metformin: New Preparations and Nonglycemic Benefits}, author={Yoshihito Fujita and Nobuya Inagaki}, journal={Current Diabetes Reports}, year={2017}, volume={17}, pages={1-10} }
Metformin has been widely used for over 5 decades. New preparations have been developed for possible enhancement of efficiency, tolerability, and pleiotropic nonglycemic effects. Extended-release metformin has contributed to adherence and improved gastrointestinal tolerability. Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma metformin levels, which might suggest use of this biguanide in patients with chronic kidney disease…
60 Citations
Metformin turns 62 in Pharmacotherapy: emergence of non-glycaemic effects and potential novel Therapeutic applications.
- Medicine, BiologyEuropean journal of pharmacology
- 2021
Metformin: clinical use in type 2 diabetes
- Medicine, BiologyDiabetologia
- 2017
With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more robust evidence for cardioprotection, metformin’s established role as ‘foundation therapy’ in type 2 diabetes may justifiably be challenged.
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
- Biology, MedicineNature Reviews Endocrinology
- 2019
Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still…
Optimizing diabetes treatment in the presence of obesity
- Medicine, BiologyCleveland Clinic Journal of Medicine
- 2017
The authors review medications approved for the treatment of type 2 diabetes mellitus that also have weight loss as a side effect and discuss glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, neuroendocrine peptide hormones, alpha-glUCosidase inhibitors, and metformin.
Metformin inhibits the activation of melanocortin receptors 2 and 3 in vitro: A possible mechanism for its anti-androgenic and weight balancing effects in vivo?
- Biology, MedicineThe Journal of Steroid Biochemistry and Molecular Biology
- 2020
Metformin Used for Weight Loss by Non-Diabetic Sudanese Females
- Medicine
- 2020
It is concluded that women who used Metformin over the counter had a good experience with it especially when combined with diet and exercise.
Clinical efficacy of metformin combined with lifestyle intervention for treatment of childhood obesity with hyperinsulinemia
- Medicine
- 2019
Metformin combined with lifestyle intervention can more effectively treat obese children with hyperinsulinemia, improving insulin resistance.
Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
- MedicineDiabetes research and clinical practice
- 2021
AIM
To compare the efficacy and tolerability metformin extended-release (MXR) and the conventional metformin immediate-release (MIR) in adults with type 2 diabetes mellitus (T2DM) METHODS: PubMed,…
Pharmacotherapy of type 2 diabetes: An update and future directions.
- MedicineMetabolism: clinical and experimental
- 2022
Time course and dose effect of metformin on weight in patients with different disease states
- MedicineExpert review of clinical pharmacology
- 2020
Within the metformin dose range from 21 RCTs, no significant dose–response relationship was observed, however, the time–course relationship is obvious for efficacy of met formin on weight.
References
SHOWING 1-10 OF 121 REFERENCES
METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
- MedicineEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
- 2016
Evidence that metformin is safe in patients with HF and associated with a reduction in newly incident HF and in HF mortality is found; there is evidence that individuals with CKD-3, who are at increased cardiovascular risk, stand to benefit from meetformin therapy.
Metformin: an old but still the best treatment for type 2 diabetes
- MedicineDiabetology & Metabolic Syndrome
- 2013
The role of metformin in the treatment of patients with type 2 diabetes is reviewed, its potential role for a variety of insulin resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes, cancer, and neuroprotection are discussed.
Metformin and the gastrointestinal tract
- Biology, MedicineDiabetologia
- 2015
It is believed that metformin response and tolerance is intrinsically linked with the gut, and how this can affect the efficacy of meetformin treatment in the individual, and contribute to the side effects associated with met formin intolerance.
The “slower” the better
- Medicine, BiologyJournal of Endocrinological Investigation
- 2014
Metformin is primarily used to treat type 2 diabetes, but it is also beneficial in the treatment of other metabolic diseases such as the polycystic ovarian syndrome (PCOS) and the non alcoholic fat liver disease (NAFLD).
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
- Biology, MedicinePloS one
- 2014
It is found that metformin withdrawal was associated with a reduction of active and total GLP-1 and elevation of serum bile acids, especially cholic acid and its conjugates, which reversed when meetformin was restarted.
Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
- MedicineDiabetology & metabolic syndrome
- 2010
Patients switched to extended release metformin XR derived the same clinical and metabolic benefits as for standard metform in hospital based outpatients with type 2 diabetes mellitus but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication.
Metformin improves healthspan and lifespan in mice
- Medicine, BiologyNature Communications
- 2013
It is shown that long-term treatment with metformin starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic.
Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
- MedicineCurrent medical research and opinion
- 2004
In this retrospective chart review, patients switched from immediate-release metformin to met formin-XR experienced fewer GI side effects on comparable doses of the extended-release meetformin.
Repurposing metformin for cancer treatment: current clinical studies
- Medicine, BiologyOncotarget
- 2016
The role of metformin as a potential cancer treatment is reviewed to critically review the results of a small number of completed trials.
Metformin in women with PCOS, Pros
- Medicine, BiologyEndocrine
- 2014
Although this drug should not be used as a first-line treatment for ovulatory dysfunctions in adult women with PCOS, there are data supporting the suggestion that in many cases pretreatment with metformin may favor ovulatory response to clomiphene citrate.